Health CanadaGeneral Alert
Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resista...
Published: April 28, 2021Recall ID: 62381Category: generalCountry: Canada
Reason for Recall / Hazard
COVID - Product safety
Product Description & Identification
Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resistant SARS-CoV-2 Variants
Additional Source Details
| Field | Value |
|---|---|
| N I D | 62381 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/bamlanivimab-potential-risk-treatment-failure-due-circulation-resistant-sars-cov-2 |
| Issue | COVID - Product safety |
| Title | Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resistant SARS-CoV-2 Variants |
| Archived | 0 |
| Category | Biologic or vaccine |
| Last updated | 2021-04-28 |
| Organization | Marketed health products |